Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer Group contraceptive patent declined

Bayer Group contraceptive patent declined

5th March 2008

International healthcare and nutrition company Bayer Group (BG) has had the patent for a recent oral contraceptive declined, it has emerged.

It is reported that the company, which is based in Germany and offers diabetes and animal health solutions among its products, has been told that its 531 Yasmin patent will not be ruled as valid.

The decision was made this week by the a New Jersey court, which upheld a challenge for the patent by generic pharmaceutical manufacturer Barr Laboratories.

Bayer is thought to be in preparation to challenge the decision of the court and is currently said to be considering its legal options in regard to defending the intellectual property.

The company fears that the decision could affect the marketing of its Yaz line of oral contraceptives which was given approval and launched in 2006.

Yaz claims to be the only birth control product “proven to treat emotional and physical premenstrual symptoms that are severe enough to impact the lives of women who choose the Pill for contraception”, according to the company website.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.